NASDAQ:NEOS - Neos Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.25 -0.35 (-4.61 %)
(As of 05/22/2018 08:00 AM ET)
Previous Close$7.60
Today's Range$7.17 - $7.75
52-Week Range$6.30 - $13.15
Volume234,700 shs
Average Volume219,641 shs
Market Capitalization$220.38 million
P/E Ratio-2.71
Dividend YieldN/A
Beta-0.21

About Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics logoNeos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.

Receive NEOS News and Ratings via Email

Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300

Debt

Debt-to-Equity Ratio-13.08
Current Ratio1.82
Quick Ratio1.49

Price-To-Earnings

Trailing P/E Ratio-2.71
Forward P/E Ratio-4.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.02 million
Price / Sales8.40
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book26.85

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-66,240,000.00
Net Margins-211.13%
Return on Equity-586.25%
Return on Assets-58.31%

Miscellaneous

Employees138
Outstanding Shares29,000,000

Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics (NASDAQ:NEOS) released its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.02. The business earned $10.73 million during the quarter. Neos Therapeutics had a negative net margin of 211.13% and a negative return on equity of 586.25%. View Neos Therapeutics' Earnings History.

When is Neos Therapeutics' next earnings date?

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Neos Therapeutics.

What price target have analysts set for NEOS?

5 equities research analysts have issued 12 month target prices for Neos Therapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate Neos Therapeutics' share price to reach $15.25 in the next year. View Analyst Ratings for Neos Therapeutics.

What are Wall Street analysts saying about Neos Therapeutics stock?

Here are some recent quotes from research analysts about Neos Therapeutics stock:
  • 1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis 1) On 01/10/18 NEOS announced that study findings for two of its ADHD medications, ER, were presented in three posters at the upcoming 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD), on 02/20/18 PDL Biopharma (Not Covered) announced termination of interest in acquiring 02/26/18 NEOS announced the U.S. launch of Adzenys ER, making it NEOS’s third ADHD product launch in less than two years; 4) as discussed at the company’s analyst day in March of 2018, NEOS plans to advance its drug candidate for the treatment of nausea and vomiting into the clinic in 2H18 and to identify one additional branded product candidate in CNS or gastroenterology in 2018; and 5) as of 03/31/18 the company held $37.2MM in cash and cash equivalents." (5/9/2018)
  • 2. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (3/22/2018)

Who are some of Neos Therapeutics' key competitors?

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the folowing people:
  • Dr. Vipin K. Garg, CEO, Pres & Director (Age 60)
  • Mr. Richard I. Eisenstadt M.B.A., Chief Financial Officer (Age 60)
  • Mr. Thomas P. McDonnell, Chief Commercial Officer (Age 46)
  • Mr. Russ McMahen, VP of R&D
  • Dr. Carolyn R. Sikes Ph.D., VP of Clinical Affairs

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Has Neos Therapeutics been receiving favorable news coverage?

Headlines about NEOS stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neos Therapeutics earned a news sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the company an impact score of 47.86 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Neos Therapeutics' major shareholders?

Neos Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (7.93%), BlackRock Inc. (6.33%), Lyon Street Capital LLC (5.02%), Russell Investments Group Ltd. (2.86%), Cortina Asset Management LLC (2.13%) and Sphera Funds Management LTD. (1.11%). Company insiders that own Neos Therapeutics stock include Bryant Fong, Juergen Martens and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.

Which major investors are selling Neos Therapeutics stock?

NEOS stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Cortina Asset Management LLC, Timpani Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for Neos Therapeutics.

Which major investors are buying Neos Therapeutics stock?

NEOS stock was purchased by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Russell Investments Group Ltd., Sphera Funds Management LTD., Millennium Management LLC, Allianz Asset Management GmbH, Quantitative Systematic Strategies LLC, OMERS ADMINISTRATION Corp and New York State Common Retirement Fund. Company insiders that have bought Neos Therapeutics stock in the last two years include Bryant Fong, Juergen Martens and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.

How do I buy shares of Neos Therapeutics?

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of NEOS stock can currently be purchased for approximately $7.25.

How big of a company is Neos Therapeutics?

Neos Therapeutics has a market capitalization of $220.38 million and generates $25.02 million in revenue each year. The company earns $-66,240,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Neos Therapeutics employs 138 workers across the globe.

How can I contact Neos Therapeutics?

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]


MarketBeat Community Rating for Neos Therapeutics (NEOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neos Therapeutics (NASDAQ:NEOS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Neos Therapeutics in the last 12 months. Their average twelve-month price target is $15.25, suggesting that the stock has a possible upside of 110.34%. The high price target for NEOS is $20.00 and the low price target for NEOS is $12.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.672.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.25$15.25$14.8333$14.8333
Price Target Upside: 110.34% upside72.90% upside33.63% upside42.63% upside

Neos Therapeutics (NASDAQ:NEOS) Consensus Price Target History

Price Target History for Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics (NASDAQ:NEOS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Cantor FitzgeraldReiterated RatingBuy$20.00MediumView Rating Details
3/17/2018Wells FargoSet Price TargetBuy$14.00LowView Rating Details
1/31/2018BMO Capital MarketsDowngradeOutperform ➝ Market PerformHighView Rating Details
10/26/2017CowenReiterated RatingBuyN/AView Rating Details
8/8/2017Royal Bank of CanadaSet Price TargetOutperform$12.00MediumView Rating Details
3/20/2017UBSReiterated RatingHoldN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Neos Therapeutics (NASDAQ:NEOS) Earnings History and Estimates Chart

Earnings by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics (NASDAQ:NEOS) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.52 EPS
Next Year EPS Consensus Estimate: $-0.1 EPS

Neos Therapeutics (NASDAQ NEOS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.43)N/AView Earnings Details
5/9/2018Q1 2018($0.48)($0.50)$10.73 millionViewListenView Earnings Details
3/15/2018Q4 2017($0.61)($0.49)$9.30 million$7.79 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.80)($0.58)$6.70 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.83)($0.83)$4.91 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.9380)($0.87)$5.63 millionViewListenView Earnings Details
3/14/2017Q4 2016($1.36)($1.14)$3.50 millionViewN/AView Earnings Details
11/10/2016Q3 2016($1.64)($1.61)$1.58 millionViewN/AView Earnings Details
8/11/2016Q2($1.16)($1.65)$1.48 million$1.49 millionViewListenView Earnings Details
5/16/2016Q1($0.87)($0.79)$1.50 million$2.58 millionViewListenView Earnings Details
3/17/2016Q4($0.66)($0.57)$1.70 millionViewListenView Earnings Details
11/10/2015Q3 2015($0.62)$0.22 millionViewN/AView Earnings Details
9/3/2015Q215($4.31)($7.76)$1.70 million$1.48 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Neos Therapeutics (NASDAQ:NEOS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Neos Therapeutics (NASDAQ NEOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.17%
Institutional Ownership Percentage: 52.51%
Insider Trading History for Neos Therapeutics (NASDAQ:NEOS)
Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics (NASDAQ NEOS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/31/2016Bryant FongDirectorBuy1,500$6.54$9,810.001,500View SEC Filing  
8/25/2016Richard I EisenstadtCFOBuy3,710$6.82$25,302.203,710View SEC Filing  
6/13/2016Juergen MartensInsiderBuy10,000$9.90$99,000.0010,000View SEC Filing  
5/19/2016Alan L HellerDirectorBuy10,000$7.61$76,100.00379,888View SEC Filing  
5/19/2016Thomas P McdonnellInsiderBuy3,000$7.56$22,680.003,000View SEC Filing  
5/18/2016Gregory J RobitailleDirectorBuy7,442$7.55$56,187.1055,677View SEC Filing  
4/20/2016Presidio Partners 2007, L.P.Major ShareholderSell20,367$9.98$203,262.661,575,419View SEC Filing  
4/15/2016Presidio Partners 2007, L.P.Major ShareholderSell57,968$10.23$593,012.641,623,997View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neos Therapeutics (NASDAQ NEOS) News Headlines

Source:
DateHeadline
Should You Be Concerned About Neos Therapeutics Inc’s (NASDAQ:NEOS) Shareholders?Should You Be Concerned About Neos Therapeutics Inc’s (NASDAQ:NEOS) Shareholders?
finance.yahoo.com - May 18 at 10:21 AM
Neos Therapeutics (NEOS) Downgraded by ValuEngine to Strong SellNeos Therapeutics (NEOS) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - May 15 at 10:14 AM
Neos Therapeutics to Present at the UBS Global Healthcare ConferenceNeos Therapeutics to Present at the UBS Global Healthcare Conference
finance.yahoo.com - May 15 at 9:26 AM
Neos Therapeutics (NEOS) Posts  Earnings Results, Misses Expectations By $0.02 EPSNeos Therapeutics (NEOS) Posts Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 11 at 8:10 PM
Neos Therapeutics (NEOS) Lowered to "Sell" at ValuEngineNeos Therapeutics (NEOS) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - May 10 at 8:13 PM
Neos Therapeutics misses by $0.03, beats on revenueNeos Therapeutics misses by $0.03, beats on revenue
seekingalpha.com - May 10 at 9:14 AM
Edited Transcript of NEOS earnings conference call or presentation 9-May-18 12:30pm GMTEdited Transcript of NEOS earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 9:14 AM
Neos Therapeutics (NEOS) "Buy" Rating Reaffirmed at Cantor FitzgeraldNeos Therapeutics' (NEOS) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 6:58 PM
BRIEF-Neos Therapeutics Reports Q1 Loss Per Share $0.50BRIEF-Neos Therapeutics Reports Q1 Loss Per Share $0.50
www.reuters.com - May 9 at 4:52 PM
Neos Therapeutics (NEOS) CEO Vipin Garg on Q1 2018 Results - Earnings Call TranscriptNeos Therapeutics' (NEOS) CEO Vipin Garg on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:52 PM
Neos Therapeutics: 1Q Earnings SnapshotNeos Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:06 AM
Neos Therapeutics Reports First Quarter 2018 Financial ResultsNeos Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:06 AM
Neos Therapeutics (NEOS) Upgraded by ValuEngine to "Hold"Neos Therapeutics (NEOS) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 2 at 11:37 PM
Form 4 Neos Therapeutics, Inc. For: Apr 27 Filed by: Szyper Linda MForm 4 Neos Therapeutics, Inc. For: Apr 27 Filed by: Szyper Linda M
www.streetinsider.com - May 2 at 4:51 PM
Neos Therapeutics (NEOS) Expected to Announce Earnings of -$0.51 Per ShareNeos Therapeutics (NEOS) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - May 2 at 11:24 AM
Neos Therapeutics to Host First Quarter 2018 Financial Results Conference Call on May 9, 2018Neos Therapeutics to Host First Quarter 2018 Financial Results Conference Call on May 9, 2018
finance.yahoo.com - May 2 at 8:55 AM
Neos Therapeutics (NEOS) Receives Average Recommendation of "Hold" from BrokeragesNeos Therapeutics (NEOS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 2 at 1:58 AM
Research Report Identifies Flexsteel Industries, Second Sight Medical Products, XG Technology, CRA International, Inc, Neos Therapeutics, and Tech Data with Renewed Outlook — Fundamental Analysis, Calculating Forward MovementResearch Report Identifies Flexsteel Industries, Second Sight Medical Products, XG Technology, CRA International, Inc, Neos Therapeutics, and Tech Data with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - May 1 at 8:56 AM
Neos Therapeutics (NEOS) Set to Announce Earnings on MondayNeos Therapeutics (NEOS) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 12:34 PM
Neos Therapeutics (NEOS) Cut to Hold at Zacks Investment ResearchNeos Therapeutics (NEOS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 11:37 AM
Zacks: Brokerages Expect Neos Therapeutics (NEOS) Will Announce Earnings of -$0.51 Per ShareZacks: Brokerages Expect Neos Therapeutics (NEOS) Will Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 15 at 11:11 AM
Royal Bank of Canada Analysts Give Neos Therapeutics (NEOS) a $12.00 Price TargetRoyal Bank of Canada Analysts Give Neos Therapeutics (NEOS) a $12.00 Price Target
www.americanbankingnews.com - April 12 at 11:29 AM
Neos Therapeutics (NEOS) Downgraded to Hold at Zacks Investment ResearchNeos Therapeutics (NEOS) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 8 at 11:55 PM
Neos Therapeutics Inc (NEOS) Receives Consensus Rating of "Hold" from BrokeragesNeos Therapeutics Inc (NEOS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 7 at 1:46 AM
Neos Therapeutics (NEOS) Upgraded at Zacks Investment ResearchNeos Therapeutics (NEOS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM
Zacks Investment Research Downgrades Neos Therapeutics (NEOS) to SellZacks Investment Research Downgrades Neos Therapeutics (NEOS) to Sell
www.americanbankingnews.com - April 6 at 1:26 PM
Neos Therapeutics (NEOS) Earns "Buy" Rating from CowenNeos Therapeutics (NEOS) Earns "Buy" Rating from Cowen
www.americanbankingnews.com - April 4 at 6:54 PM
When Will Neos Therapeutics Inc (NASDAQ:NEOS) Turn A Profit?When Will Neos Therapeutics Inc (NASDAQ:NEOS) Turn A Profit?
finance.yahoo.com - April 4 at 4:40 PM
Zacks Investment Research Upgrades Neos Therapeutics (NEOS) to HoldZacks Investment Research Upgrades Neos Therapeutics (NEOS) to Hold
www.americanbankingnews.com - April 3 at 9:54 PM
Neos Therapeutics (NEOS) PT Set at $20.00 by Cantor FitzgeraldNeos Therapeutics (NEOS) PT Set at $20.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 30 at 12:05 PM
Neos Therapeutics (NEOS) Rating Increased to Hold at BidaskClubNeos Therapeutics (NEOS) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM
Neos Therapeutics (NEOS) Upgraded to Hold by Zacks Investment ResearchNeos Therapeutics (NEOS) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:46 PM
Neos Therapeutics Inc (NASDAQ:NEOS): Time For A Financial Health CheckNeos Therapeutics Inc (NASDAQ:NEOS): Time For A Financial Health Check
finance.yahoo.com - March 23 at 6:14 PM
Cantor Fitzgerald Analysts Give Neos Therapeutics (NEOS) a $20.00 Price TargetCantor Fitzgerald Analysts Give Neos Therapeutics (NEOS) a $20.00 Price Target
www.americanbankingnews.com - March 23 at 3:17 PM
Neos Therapeutics Inc Forecasted to Post FY2018 Earnings of ($1.86) Per Share (NEOS)Neos Therapeutics Inc Forecasted to Post FY2018 Earnings of ($1.86) Per Share (NEOS)
www.americanbankingnews.com - March 23 at 10:38 AM
Neos Therapeutics (NEOS) Given a $14.00 Price Target by Wells Fargo AnalystsNeos Therapeutics (NEOS) Given a $14.00 Price Target by Wells Fargo Analysts
www.americanbankingnews.com - March 18 at 10:24 AM
Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results - GlobeNewswire (press release)Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 17 at 4:58 PM
Neos Therapeutics (NEOS) Releases Quarterly  Earnings Results, Beats Estimates By $0.12 EPSNeos Therapeutics (NEOS) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - March 16 at 8:52 AM
Neos Therapeutics (NEOS) Given a $20.00 Price Target at Cantor FitzgeraldNeos Therapeutics (NEOS) Given a $20.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 15 at 3:44 PM
Neos Therapeutics, Inc. to Host Earnings CallNeos Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 10:10 AM
Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial ResultsNeos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 15 at 10:10 AM
Are Earnings Prospects Improving For Loss-Making Neos Therapeutics Inc’s (NASDAQ:NEOS)?Are Earnings Prospects Improving For Loss-Making Neos Therapeutics Inc’s (NASDAQ:NEOS)?
finance.yahoo.com - March 15 at 10:10 AM
Head to Head Comparison: Histogenics (HSGX) & Neos Therapeutics (NEOS)Head to Head Comparison: Histogenics (HSGX) & Neos Therapeutics (NEOS)
www.americanbankingnews.com - March 13 at 9:17 AM
Neos Therapeutics Inc (NEOS) Given Average Rating of "Hold" by AnalystsNeos Therapeutics Inc (NEOS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 13 at 1:46 AM
Neos Therapeutics (NEOS) Stock Rating Upgraded by BidaskClubNeos Therapeutics (NEOS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 10 at 2:35 PM
Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017 - GlobeNewswire (press release)Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017 - GlobeNewswire (press release)
globenewswire.com - March 8 at 4:53 PM
Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017
finance.yahoo.com - March 8 at 10:20 AM
Stonepine Capital Management LLC Buys Shares of 140,000 Neos Therapeutics Inc (NEOS)Stonepine Capital Management LLC Buys Shares of 140,000 Neos Therapeutics Inc (NEOS)
www.americanbankingnews.com - March 6 at 10:03 AM
Neos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference - GlobeNewswire (press release)Neos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 5 at 4:58 PM
Neos Therapeutics to Present at the Cowen & Co. Annual Health Care ConferenceNeos Therapeutics to Present at the Cowen & Co. Annual Health Care Conference
finance.yahoo.com - March 5 at 10:02 AM

SEC Filings

Neos Therapeutics (NASDAQ:NEOS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neos Therapeutics (NASDAQ:NEOS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neos Therapeutics (NASDAQ NEOS) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.